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Abstract
Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/
EMRO region and compared to the global activity for the years 2006–2013.
Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of 
all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the 
worldwide 71.036 HSCT, and a median transplant rate of 32.8 (TR; HSCT/10 million inhabitants; 
worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006. 
HSCT activity in AFR/EMRO countries was characterized by a higher use of allogeneic compared 
to autologous HSCT, an almost exclusive use of family donors, including haploidentical family 
donors. These findings contrast with the prevalence of autologous over allogeneic HSCT, and a 
higher frequency of unrelated HSCT in other parts of the world. Of note, the increase by 200% in 
HSCT for hemoglobinopathies from 2006 to 2013 (72/year) in the AFR/EMRO region. This 
reflects the specific role of HSCT for these disease categories with high prevalence and incidence 
in the AFR/EMRO region.
This report provides information for the competent authorities to foster adequate infrastructure. It 
urges transplant organization to optimize their cooperation.
Keywords
Hematopoietic stem cell transplantation (HSCT); Global perspective; Worldwide Network for 
Blood and Marrow Transplantation (WBMT); Eastern Mediterranean Regional Organization 
(EMRO); WHO; Non-Governmental Organization (NGO); transplant rates; haploidentical 
transplants; trends; emerging technologies
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) has evolved from the beginnings of 
experimental bone marrow transplantation 60 years ago to a globally accepted successful 
therapy.1 Transplantation of hematopoietic stem cells and tissues has extended the lifespan 
and enhanced the quality of life of hundreds of thousands of patients worldwide. Over the 
last two decades, global HSCT has seen a constant evolution in technology, a decrease in 
transplant related mortality and rapid expansion. HSCT is no longer limited to younger 
patients or to patients with a matched donor. Novel conditioning regimens with lower 
intensity and new techniques have expanded the use of HSCT to older patients, to patients 
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with comorbidities and to patients with haploidentical donors1,2. Today, HSCT is an 
established but still complex form of therapy for patients with chemo- and immune-sensitive 
diseases, for the replacement of deficient cells or cellular components and other life-
threatening disorders. Its use has also been extended to severe inherited or acquired 
disorders of the hematopoietic system.
However, HSCT is still associated with significant morbidity and mortality and remains an 
example of high-cost and highly specialized medicine. It requires extensive experience, 
significant infrastructure and a network of specialists from all fields of medicine. It also 
requires the ability to provide specialist continued follow-up and management of patients. 
The accumulated experience covering a range of past errors and successes should therefore 
be used to improve access for all patients in need and serve as a model for the application of 
medical products of human origin in general.
Information on indications, the use of specific technologies and trends in HSCT is essential 
for correct patient counseling and to allow health care agencies to prepare the necessary 
infrastructure and to avoid errors in planning. In addition, the guiding principles of the 
World Health Organization (WHO; www.who.org) declare the transplantation of organs, 
cells and tissues to be a global task, with the collection of activity data being one of the 
prime prerequisites3. The Worldwide Network for Blood and Marrow Transplantation 
(WBMT; www.wbmt.org), as an umbrella organization in the field of HSCT and a Non-
Governmental Organization (NGO) in working relation with the WHO, has taken up the 
challenge of collecting and disseminating worldwide HSCT data on a regular basis. The first 
report was based on the global HSCT activity in 20064, and was followed by a report on the 
data available in 2010 and thereafter a retrospective view of the first one million HSCTs in 
the year 20155,6. The fourth report was focused on the HSCT activity in 2012 and looked at 
major trends since 20067. The report included a SWOT analysis of the current WBMT 
policy by key personnel in the field, to identify the strengths, weaknesses, opportunities and 
threats of the current perspectives in HSCT.
In the current study we analyzed the global HSCT activities reported between 2006 and 
2013 concentrating on the AFR/EMRO region in the global context regarding frequency, 
indication, donor type and geographical distribution in 2013.
PATIENTS AND METHODS
Study design
This was a retrospective survey involving all HSCT teams known to the investigators, 
organized by WBMT through established international and/or regional organizations. No 
individual patient data were used thus no ethics committee approval was mandated.
Participating Groups, Continents, Countries and Teams
In 2013, 29 teams in 12 of the 68 countries of the AFR/EMRO region reported their 
activities. In contrast, the global survey included reports from 1570 teams in 78 reporting 
countries over 6 WHO continental regions [(www.who.int/about/regions/en/) America 
(AMR/PAH; WHO regions North-, Middle and South America and Canada); Asia (SEAR/
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WPR; WHO regions South East Asia and Western Pacific Region which includes Australia 
and New Zealand); Europe (EUR; includes Turkey and Israel) and AFR/EMRO (WHO 
regions Eastern Mediterranean and Africa)]. Analyses were performed as previously 
described7.
Data were provided by the Australasian Bone Marrow Transplant Recipient Registry 
ABMTRR (www.abmtrr.org), the African Blood and Marrow Transplant Group AfBMT, the 
Asian Pacific Blood and Marrow Transplant Group APBMT (www.apbmt.org), the 
Canadian Blood and Marrow Transplant Group CBMTG (www.cbmtg.org), the Center for 
International Blood and Marrow Transplantation CIBMTR (www.cibmtr.org), the Eastern 
Mediterranean Blood and Marrow Transplant Group EMBMT (www.embmt.org), the 
European Group for Blood and Marrow Transplantation EBMT (www.ebmt.org) and the 
Latin American Blood and Marrow Transplantation Group LABMT (LABMT@wbmt.org).
Collection system and data validation were obtained as previously described7. Data were 
validated by different independent systems; through confirmation by the reporting teams, 
following receipt of a computer printout of the entered data, by selective comparison with 
MED-A/TED data sets in the EBMT or CIBMTR data system or by crosschecking with 
National Registries. On-site visits to selected teams were part of the quality control program 
within CIBMTR and EBMT teams. Based on quality controls and contacts with regulatory 
agencies or national offices, the response rate for allogeneic HSCT was estimated to be 
>95% and for autologous HSCT 80–90%. The survey focuses on the numbers of patients 
treated for the first time with HSCT. Transplant rates (TR) were computed as the number of 
HSCT per 10 million inhabitants not corrected for population age. Population data were 
obtained from the US census office (http://www.census.gov).
RESULTS
Transplant activities in the AFR/EMRO region from 2006 to 2013
Up to 34 centers from the AFR/EMRO region were noted to have HSCT activity during the 
period from 2006 to 2013 with fluctuations reflecting challenges in some centers that 
resulted in inconsistent activity over the years (Table 1 and Figures 1 and 2). In 2013, a total 
of 29 teams from 12 countries in the AFR/EMRO region provided activity data on a total of 
2331 patients. The TR in active countries ranged from 0.1 to 109 for allogeneic HSCT 
compared to 0 to 172 for autologous HSCT. Several countries had no HSCT activity (Figure 
1). Allogeneic TR ranged between 0–44 with the exception of Oman, Saudi Arabia, Jordan 
and Lebanon (69.8, 96.1, 101.1 and 108.8 TR, respectively). For autologous HSCT, the TR 
ranged between 0 and 37 with the exception of Tunisia, Jordan and Lebanon (52.6, 61.0 and 
172.8 TR, respectively). These figures reflect the limited availability of transplant teams and 
limited logistic support in many countries of the region.
In contrast to other world regions, more allogeneic (58%) than autologous (42%) HSCT 
were noted in the region (Figure 2). The AFR/EMRO region showed overall 90% increase in 
HSCT activity from 2006 to 2013 (1230 to 2331 transplants/year, respectively) with 69% 
increase in allogeneic HSCT and 129% increase in autologous HSCT (Table 1). Furthermore 
93% of patients undergoing allogeneic HSCT had a family donor and received PBSC (67%) 
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or BM (33%) as stem cell source. Cord blood transplants were in the range of 4% of all 
allogeneic HSCT. Major Increases in allogeneic HSCT were seen for hemoglobinopathies 
(200%), lymphoproliferative diseases (114%), non-malignant disorders in general (105%) 
and acute leukemias (89%; Table 1). Autologous HSCT was performed almost exclusively 
with PBSC and increased from 2006 in the African/EMRO region more than it did 
worldwide for patients with solid tumors (248% vs 9% respectively), PCD (218% vs. 76%, 
respectively) and lymphomas (107% vs.34%, respectively). As in the global survey, 
decreases were observed only in the use of autologous HSCT for leukemia (−41%). 
Interestingly, the median HSCT per center/year was higher in Africa/EMRO than global (80 
vs. 45 HSCT/center/year, respectively; see Figure 2). In comparison to the global survey, 
differences were noted in indications and donor types. The most striking differences include 
a more frequent use of allogeneic HSCT for Bone Marrow Failure (BMF; 17.9% of all 
allogeneic HSCT in Africa/EMRO as compared to 3.0% globally) and in autologous HSCT 
for Hodgkin/NHL (44.6% of all autologous HSCT in Africa/EMRO as compared to 39.2% 
globally) and almost exclusive use of family donors in allogeneic HSCT. Centers in the 
AFR/EMRO region more frequently used haploidentical donors rather than cord blood to 
perform alternative donor HSCT (Figure 3). The proportion of HSCT using haploidentical 
donors as graft source started rising from 2009 (n=41) to 2010 (n=60), fell marginally in 
2011 yet increased again in 2012 to peak in 2013 (n=74). This was in contrast to the global 
activity, in which the use of haploidentical HSCT overtook the use of unrelated CB HSCT in 
2012. Use of unrelated cord blood remained limited with 40 and 49 CB transplants in 2009 
and 2013, respectively.
Global HSCT activity, main indications and donor type in 2013.
The global HSCT activity in 2013 reached a new high of 71,036 transplants (Table 1). Most 
of the HSCT in 2013 were performed in Europe, followed by AMR/PAH, SEA/WPR and 
AFR/EMRO (47%, 30%, 20% and 3% respectively) with a steady and constant increase in 
activity in all 4 WHO regions. There was a slightly higher frequency of autologous (52.7%) 
compared to allogeneic (47.3%) HSCT. The main indications were lymphoproliferative 
disorders (n=38.029; 53%) of which 88% (n=33,447) were autologous and 12% (n=4,582) 
allogeneic HSCT; leukemias (n=25,246; 35%) of which 96% (n=24,336) were allogeneic 
and 4% (n=910) autologous HSCT; solid tumors (n=2,909; 4%) of which 4% (n=130) were 
allogeneic and 96% (n=2,779) autologous HSCT; non-malignant disorders (n=4,670; 7%) of 
which 94% (n=4,380) were allogeneic and 6% (n=290) autologous HSCT.
The median TR for all HSCT in 2013 fluctuated between regions and between participating 
countries from 390.9 in Europe (median; range 1.0 to 735.7), 204.4 in Asia (median; range 
0.7 to 610.5), 126.2 in the Americas (median; range 17.8 to 538.9) and 81.9 in AFR/EMRO 
(median; range 0.1 to 281.6). Transplant rates for allogeneic HSCT ranged from 0.1 in 
Nigeria to 450.8 in Israel (median 104.4) and transplant rates for autologous HSCT from 0.1 
in the Philippines to 437.0 in Italy (median 159.7).
The annual HSCT activity increased from 2006 to 2013 by 52.6% (Table 1) while the 
number of reporting centers increased by 17.3% and plateaued in the years 2012 – 2013 
(Figure 2). More importantly, HSCT per center increased from 35.1 to 45.2, confirming 
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increased activity per center (Figure 2). Activity increased primarily for allogeneic HSCT 
(+65% from 2006) and, among these, especially for non-malignant disorders (+86%), acute 
leukemias, MDS/MPS (+80%) and lymphoproliferative disorders (+42%; Table 1). Of all 
allogeneic HSCT, 51.4% were performed using an unrelated donor. Frequencies of 
autologous HSCT increased (+43%) most markedly in the PCD (+76%), non-malignant 
disorders (+50%) and lymphoma (+34%) subgroups. Decreased activity was reported only in 
the use of autologous HSCT for leukemias (−47%).
Special attention was given to hemoglobinopathies as indication for HSCT in the AFR/
EMRO region and worldwide. A total of 1033 HSCT were performed for these indications 
worldwide in 2013, of which 216 (21%) were reported from the AFR/EMRO region 
representing a considerable increase from the 123 HSCT in 2012. HSCT were performed in 
SEAR/WPR (n=287), Europe (n=283) and Americas (n=247; Figure 3).
Two major changes were observed during the period 2006–2013. Firstly, HSCT from 
unrelated donors became more frequent than from related donors (Figure 3). Secondly, 
mismatched family or “haploidentical” donors increased from 1.186 (6% of allogeneic 
HSCT) in 2006 to 3.830 (11.8% of allogeneic HSCT) in 2013. Worldwide, the use of 
haploidentical transplants became more common than that of unrelated cord blood in 2012 
(Figure 3).
DISCUSSION
The current analysis is based on information on more than 464,100 HSCT reported to the 
WBMT over an 8 year period and explores distribution, donor choices and HSCT techniques 
over time in the AFR/EMRO Region and worldwide. The results allow several important 
conclusions.
Firstly, HSCT activity has been steadily increasing since 2006 in all world regions (even in 
high HSCT performance regions) but to different degrees. For the first time, the number of 
HSCT per year exceeded 70,000, while there continue to be significant differences in 
transplant rates between the world regions. The relative increase was more prominent in 
countries with restricted resources, including AFR/EMRO, than in those with a high 
transplant rate, but the TR still remains the lowest rate worldwide. Many countries, 
especially in central Africa do not have an active HSCT program.
Second, there is no indication of a plateau in activity. This continuing lack of saturation 
indicates underuse and implies that more patients would have been treated by HSCT had 
they had access and had donors been available. Obviously this is more notable for 
hemoglobinopathies which are highly prevalent in AFR/EMRO regions.
Third, the activity increase worldwide is mainly caused by augmented team activity with the 
median number of HSCT per team increasing from 29 to 41 between 2006 and 2013. 
Interestingly, the existing centers in the AFR/EMRO region have a median transplant 
activity higher than the corresponding global level, indicating the need for more HSCT 
centers. However, there was no increase in HSCT/center in the analyzed region after 2007. 
This is probably a reflection of the low density of centers and a possible saturation for the 
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center activity. The increase is only in part a consequence of increased reporting from 2006 
to 2013. The proportion of uncaptured data, estimated to be less than 5% for allogeneic and 
less than 15% for autologous HSCT, also varied between the regions and was estimated to 
be lowest in the regions with the highest absolute numbers. Despite these limitations, it is 
unlikely that missing data would alter the overall interpretation.
Significant changes were observed during the study period regarding donor type and graft 
source. Overall, unrelated HSCT exceeded related donor HSCT worldwide, particularly in 
Europe8, while related HSCT remained the almost exclusive graft source in the AFR/EMRO 
region. Also, the incidence of haploidentical related HSCT was consistently higher than cord 
blood HSCT in the AFR/EMRO region, while globally this was observed only in 2012. 
From 2012 onwards, worldwide interest in the use of unrelated CB seems to have started 
decreasing, while use of haploidentical donors is consistently increasing over this period 
with a steep rise after 2012. This may reflect a learning curve with some teams reducing the 
use of cord blood in favor of adopting the newer haploidentical transplant strategies. With 
fine tuning of haploidentical transplant techniques, this may have been perceived as a more 
cost effective and logistically simpler strategy by some teams in this region. Double cord 
blood transplant, commonly used for adults, is associated with extra cost. This may also be a 
reflection of lack of unrelated donor registries and public cord blood banks in most of the 
AFR/EMRO region. Interestingly, the prominent use of allogeneic HSCT in comparison to 
autologous HSCT is a characteristic of the AFR/EMRO region.
Overall, only 1033 HSCT were performed worldwide for hemoglobinopathies, of which 
only 216 were in the AFR/EMRO region. Considering the high prevalence and incidence of 
thalassemia (40.000 born annually and 80 million carriers; Modell, WHO Bulletin 2008) and 
of sickle cell anemia (e.g. 91,011 in Nigeria and 39,743 in Congo) in the AFR/EMRO 
region, this is clearly still lagging behind demand despite the recent increase.12
Ten years after its formation, WBMT has established itself as a global umbrella organization 
for HSCT. It has accomplished one of the prime prerequisites of WHO guiding principles on 
cell, organ and tissue transplants: to collect, analyze and disseminate information on global 
transplantation activity3. More than 1500 teams from 78 countries over all 6 continents 
contributed to the survey. Lack of a regional organization in some regions remains a clear 
limitation to the global survey and is an area in which support and expertise from the 
societies of the WBMT has helped since the establishment of the organization. In fact, two 
major societies were founded with the help of the WBMT: the LABMT and the AfBMT. 
While the LABMT has already published their first survey13, the AFR/EMRO region is 
publishing its first report. Still many countries are without HSCT activities and this 
publication may aid in the development of further activity in the region.
Initiatives of WBMT involve not only registries, but also regional WBMT workshops such 
as the most recent workshop organized at King Faisal Specialist Hospital and Research 
Center, Riyadh, Saudi Arabia in January 2017, under the auspices of the WHO. 
Telemedicine approaches have been tested for their efficacy in supporting program initiation 
and are now ready to be used on a larger scale. The WBMT has also been involved in 
counseling African countries planning to start an HSCT program.
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The special position the WBMT has come to occupy as coordinator of global information in 
HSCT, has created a unique opportunity to build up a truly comprehensive world-wide 
network of standardized and quality controlled data collection and analysis. Further 
activities aim to collect outcome data on a global level, representing a major step towards the 
realization of the WHO principle that “data collection and data analysis remain integral parts 
of the therapy”. WBMT will continue to interact with competent regulatory authorities to 
pursue the goal that costs and reimbursement for HSCT should include a component for 
comprehensive data and quality management. Obviously, in the AFR/EMRO region there is 
a need for more HSCT centers in addition to progressive growth of existing centers.
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Marseille : Hôpital Timone Enfants, Institute Paoli I. Calmettes, Marseille Bouches du 
Rhone : Centre Hospitalier Universitaire La Conception, Meaux: CHU de Meaux, Metz : 
CHR de Metz-Thionville, Montpellier : CHR Lapeyronie, Mulhouse : Hôpital du 
Hasenrain, Nantes : Hotel Dieu, CHU Nantes, Nice : Centre Antoine Lacassagne, Hôpital 
de l’Archet 1, Orleans : CHR Orléans, Hôpital de la Source, Paris : Clarmart, Hôpital 
d’Instruction des Armées Percy, Hôpital d’enfants Armand Trousseau, Hôpital Cochin, 
Hôpital Neckar des enfants malades, Hôpital Necker, Hôpital Pitié Salpétière, Hôpital 
Robert Debré, Hôpital St. Antoine, Hôpital St. Louis, Hôpital Tenon, Pessac: Hôpital du 
Haut Leveque, CHU Bordeaux, Pierre Benite : Centre Hospitalier Lyon-Sud, Poitiers : 
CHU de Poitiers, Hôpital La Miletrie, Pontoise : Hôpital René Dubos, Reims : Hôpital 
Robert Debré, Rennes: Clinique Médical Infantile, CHRU, Hôpital Pontchaillou, Roubaix: 
Hôpital V. Provo, Rouen: Centre Henri Becquerel, Hôpital Charles Nicolle, Saint Priest en 
Jarez: Institue Lucien Neuwirth, ‘Institute de Cancérologie Lucien Neuwirth, Saint 
Quentin: Centre Hôpital De Saint Quentin, St. Cloud: Institut Curie, Hôpital René 
Huguenin, Strasbourg: Hôpital de Hautepierre, Toulouse: Hôpital de Purpan, Tours: 
Hôpital Bretonneau, Vandoeuvre-les-Nancy: CHU de Brabois, Hôpital d’Enfants, 
Villejuif :Gustave Roussy Cancer Campus, Hôpital Paul Brousse, Institut G. Roussy. 
Germany, Aachen: Universitätsklinikum, Augsburg: Klinikum Augsburg, Bayreuth: 
Klinikum Bayreuth, Berg: Schön Klinik Starnberger See, Berlin: Charite Campus Virchow 
Klinikum, Charité, Campus Benjamin Franklin, Charité, Campus Virchow Klinikum, 
HELIOS Klinikum Berlin Buch, Vivantes Klinikum Neukoellen, Bochum: 
Knappschaftskrankenhaus, Bonn: Universitätsklinikum, Braunschweig: Städtisches 
Klinikum, Bremen: Evangelistisch Diakonie-Krankenhaus GmbH, Klinikum Bremen-Mitte, 
Chemnitz: Klinikum Chemnitz GmbH, Cottbus: Carl-Thiem-Klinikum, Dresden: 
Universitätsklinikum Carl Gustav Carus, Duisburg: HELIOS Klinikum, Düsseldorf: 
Universitätsklinikum. Erlangen: Universitäts-Klinik für Kinder und Jugendliche, 
Universitätsklinikum. Essen: Evangelisches Krankenhaus Essen-Werden GmbH, 
Universitätsklinikum, West German Cancer Center, Flensburg: St. Franziskus Hospital, 
Frankfurt: J. W. Goethe Universität, KH Bethanien, KH Nordwest, Klinikum Frankfurt 
Oder, Universitätsklinikum d. J.W.Goethe. Freiburg: Universitatsklinikum. Giessen: 
Universitätsklinikum, Göttingen: Universitätsklinikum, Greifswald: Universitätsklinikum, 
Hagen: St. Marien Hospital, Halle: Universitätsklinikum, Hamburg: Asklepios Klinik 
Altona, Asklepios Klinik St. Georg, Universitätsklinikum Eppendorf, Universitätsklinikum 
Eppendorf - Onkologisches Zentrum, Hameln: Sana Klinikum Hameln-Pyrmont, Hamm: 
Evangelisches Krankenhaus, St. Marien Hospital, Hannover: Klinikum Region Siloah, 
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Medizinische Hochschule. Heidelberg: Angelika Lautenschläger-Klinik, 
Universitätsklinikum, Homburg/Saar: Universität des Saarlandes, Jena: FS Universitäts-
Kinderklinik, Universitätklinikum. Kaiserslautern: Westpfalzklinikum, Karlsruhe: 
Städtische Klinik, Kassel: Klinikum Kassel, Kiel: Universitätsklinikum Schleswig-Holstein, 
Koblenz: Stiftungsklinikum Mittelrhein, Köln: Universitätsklinikum. Leipzig: 
Universitätsklinikum, Lemgo: Klinikum Lippe, Lübeck: Sana Klinikum, 
Universitätsklinikum Schleswig Holstein, Universitätsklinikum Schleswig Holstein, 
Ludwigshafen: klinikum der Stadt. Magdeburg: Universitätsklinikum. Mainz: 
Universitätsklinikum, Mannheim: Universitätsklinikum, Marburg: Universitätsklinikum, 
Minden/Westfalen: Klinikum Minden, Möchengladbach: Klinikum Maria Hilf ll, KH St. 
Franziska, Munich: KH München Schwabing, Kinderklinikum Universität München 
Grosshadern, Klinikum Innenstadt der LMU, Klinikum Rechts der Isar, Klinikum 
Schwabing, SKH Munchen- Harlaching, Universitätsklinikum Grosshadern, Münster: 
Universitätklinikum Münster, W.-W Universitätklinikum. Nürnberg: Klinikum Nord, 
Oldenburg: Universitätsklinikum, Osnabrück: Klinikum Osnabrück, Potsdam: Klinikum 
Ernst von Bergmann, Regensburg: Universitätsklinikum. Rostock: Universitätsklinikum. 
Rotenburg-Wümme: Diakoniekrankenhaus. Siegen: St. Marien-Krankenhaus, Stuttgart: 
DiakonissenKH, Klinikum Stuttgart, Katharinenhospital, Robert Bosch Krankenhaus, 
Universitätsklinikum, Tübingen: Universitätsklinikum, Ulm: Kinderklinik 
Universitätsklinikum, Villingen: Schwarzwald-Baar Klinikum, Westerstede: Ammerland 
Klinik, Wiesbaden: Deutsche Klinik für Diagnostik, Dr. Horst Schmidt Klinikum, 
Würzburg: Universitätsklinikum. Greece, Alexandroupolis: Thrace University Med. 
School, Athens: Aghia Sophia Children’s Hospital, Alexandra Hospital, University of 
Athens, Athens Medical Center, Diagnostic & Therapeutic Center ‘Hygeia’, Evanghelismos 
Hospital, Hellenic Cancer Institute St. Savas, Laikon General Hospital, University of 
Athens, Crete: University Hospital, Patras: University Medical School Hospital, 
Thessaloniki: The George Papanicolaou General Hospital. Hungary, Budapest: St Istvan 
& St. Lazlo Hospitals, Szent Laszlo Hospital, Debrecen: University of Debrecen, Miskolc: 
GYEK, Postgraduate Medical School, Pécs: University of Pécs. Iceland, Reykjavik: 
National University Hospital. Ireland, Dublin: Our Lady’s Hospital of Sick Children, 
Crumlin, St. Vincent’s Hospital, St. James Hospital. Galway: University College Hospital. 
Israel, Haifa: Rambam Medical Center, Jerusalem: Hadassah University Hospital, Petach-
Tikva: Beilinson Hospital, Children’s Medical center, Revohot: Kaplan Hospital, Tel Aviv: 
Dana-Dwek Children’s Hospital, Sourasky Medical Centre, Sourasky Medical Center, Tel 
Hashomer: Chaim Sheba Medical Center, Sheba Medical Center. Italy, Alessandria: S.S. 
Antonio e Biagio e C. Arrigo. Ancona: Ancona University, Azienda Ospedale Salesi 
Riuniti, Ascoli Piceno: Mazzoni Hospital, Avellino: A.O.S. Guiseppe Moscati, Aviano: 
CRO Aviano, Bari: Universitá degli Studi di Bari. Bergamo: ASST Papa Giovanni XXIII, 
Bologna: Instituto Ortopedico Rizzoli, Poli. S. Orsola, San Orsola-Malpighi Hospital, 
Bolzano : Ospedale S. Maurizio, Brescia: Azienda Spedali Civili, Azienda Spedali Civili, 
Universitá degli Studi di Brescia, Brindisi: Perrino Hospital, Busto Arsizio: Ospedale di 
circolo di Busto Arsizio, Cagliari: Binaghi BMT Centre, Ospedale A. Businco, Ospedale 
per le Microcitemie . Catania: Ospedale Ferrarotto, University of Catania, Ospedale 
Ferrarotto, University of Catania. Civitanove Marche: Ospedale di Civitanova Marche, 
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Cremona: U.O. Ematologia CTMO, Cuneo: Azienda Ospedale “S. Croce e Carle”, 
Ferrara: University of Ferrara, Florence: Ospedaliera Universitaria di Careggi, Foggia: 
Azienda Ospedaliero Universitaria, Genova: Istituto Giannina Gaslini, Ospedale San 
Martino, Ospedale San Martino, Latina: Ospedale S. Maria Goretti, Lecce: Opsedale Vito 
Fazzi de Lecce, Medola: Istituto Scientifico Romagnolo, IRST, Messina: Policlinico 
Universitario Messina. Milan: 1st. Clinico Humanitas, Instituto Europeo di Oncologia, Ist. 
Nazionale Tumori di Milano, Istituto Scientifico H.S. Raffaele, Ospedale di Niguarda, S. 
Carlo Borromeo Hospital , University of Milan IRCCS, Mirano: Ospedale Civile di Mirano, 
Modena: University of Modena, Monza: Ospedale San Gerardo, Ospedale San Gerardo, 
Universita Di Milano-Bicocca, Napels: Cardarelli Hospital , Frederico ll University, 
Hospital Pausilipon, National Cancer Institute IRCCS, Novara: Ospedale Maggiore della 
Carita. Nuoro: Ospedale San Francesco, Padova: Centro Leucemie Infantili, Istituto 
Oncologia Veneto IOV-IRCCS, Padua: University Hospital, Pagani: Hospital A. Tortora, 
Palermo: ARNAS Civico Di Cristina, Ospedale die Bambini, Ospedale ‘La Maddalena’, 
Ospedale V. Cervello- USL 60, Uni delgi Studi di Palermo, Parma: Università degli studi, 
Pavia: Fondazione Clinica del Lavoro, S. Maugeri, IRCCS Policlinico S. Matteo, Policlinico 
IRCCS St. Matteo, Perugia: Ospedale Santa Maria della Misericordia, Pesaro: Ospedale 
San Salvatore, Pescara: Ospedale Civile, Piacenza: Hospital Guglielmo da Saliceto, Pisa: 
University of Pisa, Potenza: San Carlo Hospital, Ravenna: Ospedale Civile, Reggio di 
Calabria: Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Reggio Emilia: 
Arcispedale S. Maria Nuova, Rimini : Ospedale Infermi Rimini, Rionero in Vulture: 
IRCCS/CROB, Rome: IRRCS Ospedale Bambino Gesu, Ospedale S. Camillo, Policlinico 
Tor Vergata, Rome Transplant Network, Università “ La Sapienza”, Università Cattolica , 
Salerno: AOU San Giovanni di Dio e Ruggi D’Aragona, San Giovanni Rotondo: Hospital 
Casa Sollievo Sofferenza, Sassari: Universita Di Sassari, Siena: Ospedale Sclavo, Taranto: 
Institute of Haematologie, Ospedale Nord, Torino: Ospedale Magg. S. G. Battista, Ospedale 
Ordine Mauriziano Umberto I, University Hospital, Treviso: Presidio Ospedaliero Treviso, 
Tricase (Lecce): Hospital C. Panico, Istituto per I’Infanzia, IRCCS Burlo Garofolo. Udine: 
Policlinico Universitario & General Hospital. Varese: Ospedale di Circolo e Fondazione 
Macchi, Venice: Ospedale dell’Angelo, Verbania Pallanza: Ospedale di Verbania, Vercelli: 
S. Andrea Hospital , Verona: Policlinico G. B. Rossi, Vicenza: Ospedale S. Bortolo. 
Kazakhstan, Astana: National Research Center for Oncology and Transplantology. Latvia, 
Riga: Clinic Linezers. Lithuania, Vilnius: Santariskiu Klinikos. Lithuania, Vilnius: 
University Children’s Hospital. Luxemburg, Luxemburg, Center Hospitalier. Macedonia, 
Skopje: Medical Faculty. Netherlands, Amsterdam: Academic Med Centre, Antoni Van 
Leeuwenhoek Cancer Institute, VU University Medical Center. Enschede: Medisch 
Spectrum Twente. Groningen: University Hospital. Leiden: University Hospital. 
Maastrich: University Hospital. Nieuwegein: St. Antonius Hospital. Nijmegen: University 
Hospital. Rotterdam: Dr. Daniel den Hoed Cancer Center, Sophia Children’s Hospital. The 
Hague: Haga Hospital. Utrecht: University Hospital for Children, WKZ, Utrecht University 
Hospital UMCU. Zwolle: Isala klinieken. Norway, Bergen: Haukelands Sjukhus. Oslo: 
Oslo University Hospital, Rikshospitalet-Radiumhospitalet. Tromso: University Hospital 
North Norway. Trondheim: St. Olavs Hospital. Poland, Bydgoszcz: Nicolaus Copernicus 
University. Cracow: University Hospital CMUJ, University Children’s Hospital JUMC. 
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Gdansk: Medical University. Gliwice: Maria Curie Memorial Cancer Centre. Katowice: 
Silesian Medical Academy. Lodz: Medical University of Lodz. Lublin: Children’s 
University Hospital, University Medical School. Poznan: Institute of Pediatrics, Pozan 
Medical Academy. Warsaw: Central Clinical Hospital, Central Hospital Military Medical 
Academy, Institute of Haematology and Blood Transfusion, Marie Curie Institute. 
Wroclaw: Lower Silesian Center / BM Donor Registry, Medical Academy, University of 
Medicine. Portugal, Coimbra: University Hospital. Lisbon: H. St. Antonio dos Capuchos, 
Hospital de Santa Maria, Instituto Portugues de Oncologia. Porto: Hospital St. Joao, 
Instituto Portugues de Oncologia. Romania, Bucharest: Coltea Clinical Hospital, Fundeni 
Clinical Institute. Targu-Mures: Sectia Clinica de Hematologie. Timisoara: Children’s 
Hospital Louis Turcanu. Russia, Ekaterinburg: Regional Hospital No. 1. Moscow: 
Burnasyan Fed. Med. Biophysical Centre, Cancer Research Center, Cancer Research Centre, 
Federal Research Center for Pediatric Hematology, Main Military Clinical Hospital, 
National Pirogov Medical Centre, Research Haematology Center of RAS, The Russian 
Children’s Research Hospital. St. Petersburg: Federal Centre V.A. Almazov, First State 
Pavlov Medical University, Russian Scientific and Research Institute of Haematology. 
Serbia, Belgrade: Clinical Center of Serbia, Military Medical Academy, Mother and Child 
Health Institute. Slovak Republic, Banská Bystrica: Roosevelt Hospital. Bratislava: 
National Cancer Institute, University Hospital. Kosice: University Hospital. Slovenia, 
Ljublijana: University Medical Centre. Spain, Alicante: Hospital General. Barakaldo 
Vizcaya: Hospital de Cruces. Barcelona: Hospital Clinic, Hospital General Vall d’Hebron, 
Hospital Germans Trias i Pujol , Hospital M. Infantil, Vall d’Hebron, Hospital Mutua de 
Terrassa, Hospital Sant Joan de Deu, Institute Catala d’Oncologia, Hospital Duran i Reynals, 
Santa Creu i Sant Pau, Santa Creu i San Pau. Caceres: Hospital San Pedro de Alcantara. 
Cadiz: Hospital de Jérez, Hospital Universitario Puerta del Mar. Castellon de La Plana: 
Hospital General de Castellon. Cordoba: Hospital Reina Sofia. Galdakao: Hospital de 
Galdakao. Girona: Institut Catala d’Oncologia, Josep Trueta. Granada: Hospital Virgen de 
la Nieves. Jaen: Hospital Cuidad de Jaen. La Coruna : Complexo Hosp. Uni. A Coruna. La 
Laguna, Tenerife: University Hospital Canary Isles, Hospital N. S. De la Candelaria. Las 
Palmas Canary Isles: Hospital Insular, Hospital Materno Infantil, Hospital Universitario de 
Gran Canaria ‘Dr. Negrin’. Leon: Hospital Universitario de Leon. Lleida: Hospital Arnau 
de Vilanova. Logrono: Hospital San Pedro, La Rioja. Lugo: Hospital Lucus Augusti. 
Madrid: Clinica Moncloa, Fundacion Jimenez Diaz, Hospital de la Princesa, Hospital Doce 
de Octubre, Hospital General Universitario Gregorio Maranon, Hospital La Paz, Hospital 
Niño Jesus, Hospital Principe Asturias, Alcala de Henares, Hospital Quiron, Hospital 
Ramon y Cajal, Hospital Severo Ochoa, Leganés, Hospital Univeristario Materno Infantil 
Gregorio Maranon, Hospital Universitario de Getafe, Hospital Universitario Puerta de 
Hierro, Hospital Universitario San Carlos. Malaga: Carlos Haya Hospital. Murcia: Hospital 
General Universitario Morales Meseguer, Hospital Virgen de la Arrixaca. Orense: Com. 
Hospital Cristal-Pinor. Oviedo: Hospital Covadonga, Central Asturias. Palma de Mallorca: 
Hospital son Llatzer, Hospital Universitario Son Espases (Son Dureta). Pamplona: Clinica 
Universitaria de Navarra, Hospital de Navarra. Pontevedra: Hospital Montecelo. 
Salamanca: Complejo Hospital. San Sebastian: Hospital Universitario Donostia. 
Santander: Hospital Universitario M. de Valdecilla. Santiago de Compostela: Hospital 
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Clinico Universitario. Sevilla: Hospital Universitario Virgen del Rocio. Valencia: Hospital 
Arnau de Vilanova de Valencia, Hospital Clinico Universitario, Hospital Doctor Peset, 
Hospital Universitario La Fe, Instituto Valenciano de Oncologia. Valladolid: Hospital Rio 
Hortega. Vigo: CHUVI Hospital Alvaro Cunqueiro. Zaragoza: Clinico Universitario 
Lozano Blesa, Hospital Miguel Servet. Sweden, Goteborg: CHECT Sahlgrenska University 
Hospital. Linköping: University Hospital. Lund: University Hospital. Örebro: Medical 
Center Hospital. Stockholm: Karolinska University Hospital. Umea: University Hospital. 
Uppsala: University Hospital. Switzerland, Aarau: Kantonsspital Aarau. Basel: University 
Hospital Basel. Bellinzona: Ospedale San Giovanni. Bern: Inselspital. Geneva: Hôpital 
Cantonal Universitaire. Lausanne: Centre Hospitalier Universitaire Vaudois. St. Gallen: 
Kantonsspital. Zurich: University Hospital, Universitäts Kinderklinik. Turkey, Adana: 
Baskent University Adana, Cukurova University Balcali Hospital. Ankara: Ankara Bayindir 
Hospital, Ankara University Faculty of Medicine, Dikimevi, Ankara Children’s Hospital, 
GATA BMT Center, Etlik, Gazi University Medical School, Besevler, Gazi University 
Medical School, Besevler, Hacettepe University Medical School, Sihhiye, Ihsan Dogramaci 
Children’s Hospital (Hacettepe), Numune Education and Research Hospital, Private 
Medicana International Hospital, University Faculty of Medicine, Cebeci, University of 
Ankara, Cebeci. Antalya: Akdeniz University School of Medicine, Medical Park Antalya 
Hospital, Lara, Medical Park Hospitals, Medstar Antalya Hospital, Cakirlar. Atakum 
Samsun: Medicalpark Hospital. Aydin: Adnan Menderes University Medical Faculty. 
Bursa: Uludag University Scool of Medicine. Eskisehir: Osmangazi University. 
Gaziantep: University Medical School. Istanbul: Acibadem Altunizade Hospital, 
Acibadem University Atakent Hospital, Bahcelievler Medical Park Hospital, Cerrahpasa 
Medical Faculty, Florence Nightingale Sisli Hospital, Istanbul Medipol University, Medical 
Park Goztepe, University of Istanbul, Hisar Intercontinental Hospital Izmir: Dokuz Eylul 
University, Ege University Medical Faculty, Bornova, Tepecik Research and Educational 
Hospital. Kayseri: Erciyes University Faculty of Medicine, Erciyes University Hospital. 
Kocaeli: Anadolu Medical Center Hospital. Konya: Necmettin Erbakan, Meram University 
Medical Hospital. Malatya: Inonu University Targut Özal Medical Centre, Samsun: 
Ondokuz Mayis University. Trabzon: Karadeniz Technical University. Ukraine, Kiev: City 
BMT Center, National Pediatric Specialized Hospital, OHMATDYT. United Kingdom, 
Aberdeen: The Royal Infirmary. Bangor: Ysbyty Gwynedd. Bath: Royal United Hospital. 
Belfast: Belfast City Hospital Trust. Birmingham: Heartlands Hospital, Queen Elizabeth 
Hospital, The Birmingham Children’s Hospital. Blackpool: Victoria Hospital. 
Bournemouth: oyal Bournemouth Hospital. Bristol: Avon and Royal Hospital for Sick 
Children. Cambridge: Addenbrooke’s Hospital. Cardiff/Swansea: University Hospital of 
Wales. Cheltenham: Cheltenham General Hospital. Coventry: University Hospital & 
Warwickshire NHS Trust. Dudley: Dudley NHS Trust. Dundee: Ninewells Hospital. 
Edinburgh: The Western General Hospital. Exeter: Royal Devon and Exeter Hospital. 
Glasgow: Beatson, West of Scotland Cancer Centre, Royal Hospital for Sick Children: 
Ipswich: Ipswich Hospital. Leeds: Leeds Teaching Hospitals Trust. Leicester: Royal 
Infirmary Hospital. Liverpool: Alder Hay Children’s Hospital, Royal Liverpool University 
Hospital. London: Great Ormond, Street Hospital, Hammersmith Hospitals NHS Trust, 
King’s College Hospital, Parkside Hospital, London, Royal Marsden Hospital, Mary’s 
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Hospital, St. Bartholomew’s and the Royal London Hospital, St. George’s Hospital, The 
Harley Street Clinic, The London Clinic, The Royal Free Hospital, University College 
Hospital. Manchester: Central Manchester NHS Trust, Christie Hospital, The Royal 
Infirmary. Newcastle upon Tyne: Freeman Hospital. Norwich: Norfolk and Norwich 
Hospital. Nottingham: Nottingham City Hospital. Churchill, Stoke Manderville Hospitals. 
Plymouth: Plymouth Hospitals NHS Trust. Poole: Poole Hospital NHS Foundation Trust. 
Salisbury: Salisbury NHS Foundation Trust. Sheffield: Teaching Hospitals NHS Trust, 
Children’s Hospital. Southampton: CRC Wessex. Stoke-on-Trent: University Hospital of 
North Staffordshire. Swindon: Great Western Hospital. Taunton: Taunton and Somerset 
Hospital.
LABMT
Argentina, Buenos Aires: Hospital Universitario Fundacion Favaloro, Hospital Italiano de 
Buenos Aires, FUNDALEU, Hospital de Clinicas J de San Martin, Hospital Aleman, 
Instituto Alexander Fleming, Sanatorio Anchorena , Hospital Britànico de Buenos Aires, 
Hospital Rodolfo Rossi, Sagrado Corazón, Hospital Italiano de La Plata, Hospital San 
Martín de La Plata, CEMIC. Córdoba: Sanatorio Allende, Hospital Privado de Còrdoba. 
Pilar: Hospital Universitario Austral, El Hospital de Niños Sor María Ludovica (HNSML). 
Santa Fe: CETRAMOR. Brazil, Salvador: Monte Tabor Centro Ítalo Brasileiro de 
Promoção Sanitário - Hospital São Rafael, Hospital das Clinicas UFBA. Fortaleza: Hospital 
Universitário Walter Cantídeo - UFC – SAMEAC. Belo Horizonte: Hospital Socor. Juiz de 
Fora: Hospital Universitário da Juiz da Fora UFJF. Curitiba: Hospital das Clinicas 
Universitário Fed. Do Parana. Niteroi: Hospital Das Clinicas de Niteroi. Rio de Janiero: 
Centre de transplante de Medula Ossea INCA, Hospital Universitário Clementino Fraga 
Filho, Hospital Universitário Pedro Ernesto HUPE UERJ. Porto Alegre: Hospital das 
Clinicas de Porto Algra UFRG, Hospital das Clinicas de Porto Algra UFRG peds. Barretos: 
Hospital de Câncer de Barretos - Fundação Pio XII. Campinas: Centro de Hematologia e 
Hemoterapia de Campinas (Hemocentro) da Universidade Estadual de Campinas (Unicamp), 
Centro Infantil de Investigações Hematológicas Dr.Domingos A. Boldrini, Real Soc. 
Beneficência Portuguesa de Campinas, Hospital Vera Cruz S/A. Jau: Hospital Amaral 
Carvalho - Fundação Dr. Amaral Carvalho. Ribeirao Preto: Hospital de Clínicas FAEPA 
Ribeirão Preto FMRP USP, Hospital São Lucas de Ribeirão Preto. São Paulo: Fundação 
Antônio Prudente Hospital A C Camargo, Instituto de Oncologia Pediátrica – GRAACC – 
UNIFESP, Hospital Israelita Albert Einstein, Hospital Sírio Libanês, Hospital das Clínicas 
São Paulo - HCFMUSP, Instituto Brasileiro de Controle do Cancer IBCC, Sociedade 
Hospital Samaritano, HTEJZ - Hospital Brigadeiro - SES (Hospital Dr. Euryclides de Jesus 
Zerbini), Hospital Santa Helena - Hemome, Hospital Santa Paula, Hospital Bandeirantes, 
Hospital Nove de Julho, FCM Santa Casa de Misericórdia de São Paulo. Sorocaba: Hospital 
Unimed Sorocaba. Chile, Santiago: Hospital Del Salvador de Chile adults, Catholic 
University of Chile Adults, Catholic University of Chile Pediatrics, Clinica Santa Maria 
Adults and Pediatrics. Colombia, Bogota: Clinica de Marly. Cali: Center Medico 
Imbanaco. Floridablanca: UNAB FOSCAL. Medellin: Clinicas las Americas IDC, 
Hospital Pablo Tobin Uribe . Costa Rica, San Jose: Hospital Mexico CCSS, Hospital San 
Juan de Dios Adults. Ecuador, Guayaquil: OMNI HOSPITAL Guayaquil, SOLCA 
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Guayaquil. Quito: Hospital Metropolitano Quito. Mexico, Guadalajara: Hospital Civil de 
Pediatria Guadalajara, Juan I Menchaca, Hospital Civil de Guadalajra Frai Antonio Alcalde. 
Mexico City: Hospital Infantil de Mexico Federico Gomez HIMFG, Hospital 
Especialidades Centro Medico Nacional Siglo XXI, Instituto National de Cancerologia 
INCAN, Instituto National de Pediatria. Monterrey: Hospital Uni Antonoma de Nuevo 
Leon UANL. Puebla: Center de Hematologia y Medicina Interna -Clinica Ruiz, Hospital de 
Especialidades IMSS. Xalapa: Centro Estatal de Onco (CECAN) Dr. Miguel Dorantes 
Mesa. Panama, Panama City: Instituto Oncologico Nacional, CHAAM Complejo 
Hospitalario Metropolitano Dr. Arnulfo Arias Madrid, Hospital del Nino. Paraguay, 
Asuncion: Instituto de Prevision Social IPS. Peru, Chiclayo: Nacional Almanzor Aguinaga 
Asenjo . Lima: Hospital Rebagliati, Hospital Almenara, Nacional de Salud del Ninos, 
Clinica San Borja SANNA. Uruguay, Montevideo: Asociacion Espanola lo de Socorros 
Mutuos Fundación Pérez-Scremini/Hospital Pereira Rossell, Asociacion Espanola lo de 
Socorros Mutuos , Hospital Británico , Servicio Médico Integral-SMI, Hospital Maciel. 
Venezuela : Caracas, Hospital de Clínicas de Caracas. Valencia : Cuidad Hospital Dr. 
Enrique Tejera CHET.
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Transplant rates for allogeneic and autologous Hematopoietic Stem Cell Transplantation 
(HSCT) and number of national transplant centers in the African/EMRO region in 2013
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Worldwide trends 2006 – 2013 in numbers of allogeneic and autologous hematopoietic stem 
cell transplantations (HSCT) and number of reporting teams in the African/EMRO region 
and worldwide (upper panel). Numbers of median HSCT/team in the African/EMRO region 
and worldwide (lower panel)
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Frequencies of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) according to 
related or unrelated donors and frequencies of alternative HSCT in the AFR/EMRO region 
and worldwide (upper panel). In the lower panel HSCT for hemoglobinopathies in the four 
WHO regions.
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Table 1:








total related unrelated total total related unrelated total
Leukemia’s 492 670 50 720 46% 14392 11424 12912 24336 69%
AML 186 336 26 362 95% 6611 5592 6334 11926 80%
ALL 132 226 16 242 83% 3488 2926 2753 5679 63%
CML 139 48 0 48 -65% 1334 554 496 1050 -21%
MDS/MPS 33 52 6 58 76% 2268 1957 2745 4702 107%
CLL 2 8 2 10 400% 556 298 476 774 39%
Other leukemia 0 0 0 0 0 135 97 108 205 52%
Lymphoproliferative disorders 28 53 7 60 114% 3219 2111 2471 4582 42%
Plasma cell disorders 2 17 0 17 750% 773 450 445 895 16%
lymphomas 26 36 17 43 65% 2446 1639 2006 3645 49%
Other lymphoma/Type unknown 0 0 0 0 0 0 22 20 42 0
Solid tumors 1 0 0 0 -100% 150 85 45 130 -13%
Non malignant disorders 277 531 38 569 105% 2360 2624 1756 4380 86%
Bone Marrow Failures 154 234 8 242 57% 1292 1316 766 2082 61%
Hemoglobinopathies 72 213 3 216 200% 392 805 228 1033 164%
Immune deficiencies 41 74 16 90 120% 445 381 470 851 91%
Inherited diseases of 
metabolism
10 10 11 21 110% 177 63 154 217 23%
Autoimmune disorders 0 0 0 0 0 16 18 22 40 150%
Other Non malignant disorders 0 0 0 0 0 38 41 116 157 313%
Others 5 3 2 5 0 212 61 83 144 -32%





Leukemias 58 n.a. n.a. 34 -41% 1726 n.a. n.a. 910 -47%
Lymphoproliferative disorders 338 n.a. n.a. 840 148% 21655 n.a. n.a. 33447 65%
Plasma cell disorders 127 n.a. n.a. 404 218% 10675 n.a. n.a. 18766 76%
Lymphomas 211 n.a. n.a. 436 107% 10980 n.a. n.a. 14681 34%
Solid tumors 29 n.a. n.a. 101 248% 2560 n.a. n.a. 2779 9%
Non malignant disorders 2 n.a. n.a. 2 0 193 n.a. n.a. 290 50%
Others 0 n.a. n.a. 0 96 n.a. n.a. 38 -60%
























Total all HSCT 1230 n.a. n.a. 2331 90% 46563 n.a. n.a. 71036 53%
n.a.; not applicable
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